Arterial hypertension in elderly

Česká verzia

Authors: Filipovský Jan
Authors place of work: II. interní klinika Lékařské fakulty v Plzni, Univerzita Karlova, Fakultní nemocnice Plzeň
Published in the journal: Geriatrie a Gerontologie 2024, 13, č. 1: 7-13
Category: Review Article

Summary

Hypertension is one of the most common problems at higher age and belongs to the most important cardiovascular risk factors. Subjects aged 65 years and more have typically isolated systolic hypertension with increased pulse pressure as a consequence of decreased elasticity of central arteries. With increasing age, the prevalence of cardiovascular and renal diseases and diabetes is higher. Therefore, we use drugs that have cardiprotective effect and do not affect negatively concomitant diseases. Blockers of renin-angiotensin system, calcium channels blockers and thiazide-type diuretics are basic drugs; their combination results in effective control of hypertension. The risk of cardiovascular events and of heart failure is decreased after antihypertensive treatment also in subjects aged 80 years and more.

Keywords:

hypertension in the elderly, isolated systolic hypertension, pulse pressure, treatment of hypertension

Zdroje

1. Mancia G, Kreutz R, et al. ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA) 2023; 41: 1874–2071.

2. Widimský J, Filipovský J, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze. Doporučení České společnosti pro hypertenzi. Hypertenze a KV prevence 2022; 2: 1–25.

3. Stergiou GS, Palatini P, Parati G, et al. European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens 2021; 39: 1293–1302.

4. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years. A randomized clinical trial. JAMA doi:10.1001/jama.2016.7050.

5. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1–12.

6. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD001841. doi: 10.1002/14651858.CD001841.pub2.

7. Williams B, MacDonald TM, Morant S, et al. The British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386: 2059–2068.

8. Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med 2021; 385: 2507–2519.